MediPal Holdings Corporation Logo

MediPal Holdings Corporation

7459.T

(3.0)
Stock Price

2.459,00 JPY

2.22% ROA

6.64% ROE

13.86x PER

Market Cap.

537.482.030.617,00 JPY

0% DER

2.31% Yield

1.1% NPM

MediPal Holdings Corporation Stock Analysis

MediPal Holdings Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

MediPal Holdings Corporation Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.93x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a minimal amount of debt (6%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Assets Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

4 ROE

The stock's ROE falls within an average range (7.04%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (2.27%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

6 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

7 Dividend Growth

The company's dividend growth has shown a positive trajectory over the past three years, consistently increasing year after year, indicating a favorable trend for potential investors.

8 Dividend

Investors can take comfort in the fact that the company has consistently distributed dividends over the past three years, demonstrating a commitment to rewarding shareholders.

9 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is undervalued (210.189), making it an appealing investment prospect with its intrinsic value surpassing the current market price.

10 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

11 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

MediPal Holdings Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

MediPal Holdings Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

MediPal Holdings Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

MediPal Holdings Corporation Revenue
Year Revenue Growth
2004 1.665.902.000.000
2005 1.921.714.000.000 13.31%
2006 2.166.846.000.000 11.31%
2007 2.255.046.000.000 3.91%
2008 2.463.807.000.000 8.47%
2009 2.545.985.000.000 3.23%
2010 2.662.887.000.000 4.39%
2011 2.750.215.000.000 3.18%
2012 2.810.914.000.000 2.16%
2013 2.947.738.000.000 4.64%
2014 2.872.913.000.000 -2.6%
2015 3.028.235.000.000 5.13%
2016 3.064.041.000.000 1.17%
2017 3.146.341.000.000 2.62%
2018 3.181.935.000.000 1.12%
2019 3.253.122.000.000 2.19%
2020 3.211.173.000.000 -1.31%
2021 3.290.921.000.000 2.42%
2022 3.360.008.000.000 2.06%
2023 3.569.008.000.000 5.86%
2023 3.558.732.000.000 -0.29%
2024 3.637.268.000.000 2.16%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

MediPal Holdings Corporation Research and Development Expenses
Year Research and Development Expenses Growth
2004 0
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 118.000.000 100%
2020 106.000.000 -11.32%
2021 108.000.000 1.85%
2022 103.000.000 -4.85%
2023 0 0%
2023 991.000.000 100%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

MediPal Holdings Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
2004 6.868.000.000
2005 9.549.000.000 28.08%
2006 13.021.000.000 26.66%
2007 8.210.000.000 -58.6%
2008 7.458.000.000 -10.08%
2009 8.351.000.000 10.69%
2010 7.952.000.000 -5.02%
2011 7.902.000.000 -0.63%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 182.264.000.000 100%
2023 165.203.000.000 -10.33%
2024 160.180.000.000 -3.14%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

MediPal Holdings Corporation EBITDA
Year EBITDA Growth
2004 63.207.000.000
2005 77.445.000.000 18.38%
2006 93.453.000.000 17.13%
2007 94.482.000.000 1.09%
2008 84.801.000.000 -11.42%
2009 82.634.000.000 -2.62%
2010 79.339.000.000 -4.15%
2011 85.851.000.000 7.59%
2012 48.703.000.000 -76.27%
2013 63.543.000.000 23.35%
2014 57.284.000.000 -10.93%
2015 68.101.000.000 15.88%
2016 67.844.000.000 -0.38%
2017 74.522.000.000 8.96%
2018 78.378.000.000 4.92%
2019 82.843.000.000 5.39%
2020 67.806.000.000 -22.18%
2021 76.400.000.000 11.25%
2022 79.805.000.000 4.27%
2023 64.688.000.000 -23.37%
2023 65.313.000.000 0.96%
2024 71.134.000.000 8.18%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

MediPal Holdings Corporation Gross Profit
Year Gross Profit Growth
2004 137.805.000.000
2005 161.602.000.000 14.73%
2006 188.235.000.000 14.15%
2007 191.654.000.000 1.78%
2008 187.236.000.000 -2.36%
2009 191.091.000.000 2.02%
2010 188.147.000.000 -1.56%
2011 192.568.000.000 2.3%
2012 202.142.000.000 4.74%
2013 209.358.000.000 3.45%
2014 201.735.000.000 -3.78%
2015 217.497.000.000 7.25%
2016 219.019.000.000 0.69%
2017 228.100.000.000 3.98%
2018 232.502.000.000 1.89%
2019 236.740.000.000 1.79%
2020 214.261.000.000 -10.49%
2021 217.445.000.000 1.46%
2022 224.305.000.000 3.06%
2023 248.152.000.000 9.61%
2023 233.008.000.000 -6.5%
2024 250.396.000.000 6.94%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

MediPal Holdings Corporation Net Profit
Year Net Profit Growth
2004 8.729.000.000
2005 20.842.000.000 58.12%
2006 19.105.000.000 -9.09%
2007 27.794.000.000 31.26%
2008 12.510.000.000 -122.17%
2009 1.958.000.000 -538.92%
2010 1.704.000.000 -14.91%
2011 11.650.000.000 85.37%
2012 18.655.000.000 37.55%
2013 25.485.000.000 26.8%
2014 23.687.000.000 -7.59%
2015 30.771.000.000 23.02%
2016 29.011.000.000 -6.07%
2017 34.780.000.000 16.59%
2018 34.359.000.000 -1.23%
2019 37.968.000.000 9.51%
2020 23.926.000.000 -58.69%
2021 29.423.000.000 18.68%
2022 38.806.000.000 24.18%
2023 23.864.000.000 -62.61%
2023 41.474.000.000 42.46%
2024 36.032.000.000 -15.1%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

MediPal Holdings Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2004 46
2005 98 53.61%
2006 83 -18.29%
2007 119 31.09%
2008 52 -128.85%
2009 8 -550%
2010 7 -14.29%
2011 50 85.71%
2012 82 40.24%
2013 113 26.79%
2014 105 -7.69%
2015 136 22.96%
2016 128 -5.47%
2017 154 16.88%
2018 145 -6.21%
2019 176 17.14%
2020 114 -54.87%
2021 140 19.29%
2022 185 23.91%
2023 112 -64.29%
2023 196 42.56%
2024 172 -14.04%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

MediPal Holdings Corporation Free Cashflow
Year Free Cashflow Growth
2004 18.489.000.000
2005 32.732.000.000 43.51%
2006 7.601.000.000 -330.63%
2007 7.889.000.000 3.65%
2008 3.494.000.000 -125.79%
2009 -14.934.000.000 123.4%
2010 26.767.000.000 155.79%
2011 -18.666.000.000 243.4%
2012 40.463.000.000 146.13%
2013 -24.815.000.000 263.06%
2014 65.299.000.000 138%
2015 -16.410.000.000 497.92%
2016 12.117.000.000 235.43%
2017 33.058.000.000 63.35%
2018 45.225.000.000 26.9%
2019 29.565.000.000 -52.97%
2020 18.780.000.000 -57.43%
2021 42.339.000.000 55.64%
2022 2.642.000.000 -1502.54%
2023 0 0%
2023 42.448.000.000 100%
2024 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

MediPal Holdings Corporation Operating Cashflow
Year Operating Cashflow Growth
2004 26.301.000.000
2005 41.795.000.000 37.07%
2006 19.836.000.000 -110.7%
2007 23.964.000.000 17.23%
2008 23.370.000.000 -2.54%
2009 13.992.000.000 -67.02%
2010 49.474.000.000 71.72%
2011 -1.988.000.000 2588.63%
2012 61.769.000.000 103.22%
2013 -72.000.000 85890.28%
2014 80.466.000.000 100.09%
2015 21.985.000.000 -266%
2016 47.954.000.000 54.15%
2017 63.558.000.000 24.55%
2018 63.716.000.000 0.25%
2019 56.917.000.000 -11.95%
2020 34.448.000.000 -65.23%
2021 61.216.000.000 43.73%
2022 16.146.000.000 -279.14%
2023 0 0%
2023 61.843.000.000 100%
2024 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

MediPal Holdings Corporation Capital Expenditure
Year Capital Expenditure Growth
2004 7.812.000.000
2005 9.063.000.000 13.8%
2006 12.235.000.000 25.93%
2007 16.075.000.000 23.89%
2008 19.876.000.000 19.12%
2009 28.926.000.000 31.29%
2010 22.707.000.000 -27.39%
2011 16.678.000.000 -36.15%
2012 21.306.000.000 21.72%
2013 24.743.000.000 13.89%
2014 15.167.000.000 -63.14%
2015 38.395.000.000 60.5%
2016 35.837.000.000 -7.14%
2017 30.500.000.000 -17.5%
2018 18.491.000.000 -64.95%
2019 27.352.000.000 32.4%
2020 15.668.000.000 -74.57%
2021 18.877.000.000 17%
2022 13.504.000.000 -39.79%
2023 0 0%
2023 19.395.000.000 100%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

MediPal Holdings Corporation Equity
Year Equity Growth
2004 168.104.000.000
2005 242.413.000.000 30.65%
2006 261.111.000.000 7.16%
2007 290.692.000.000 10.18%
2008 294.500.000.000 1.29%
2009 330.992.000.000 11.03%
2010 340.983.000.000 2.93%
2011 354.343.000.000 3.77%
2012 381.889.000.000 7.21%
2013 407.478.000.000 6.28%
2014 457.602.000.000 10.95%
2015 488.326.000.000 6.29%
2016 521.163.000.000 6.3%
2017 572.655.000.000 8.99%
2018 592.847.000.000 3.41%
2019 607.422.000.000 2.4%
2020 638.932.000.000 4.93%
2021 649.087.000.000 1.56%
2022 688.054.000.000 5.66%
2023 714.615.000.000 3.72%
2023 736.612.000.000 2.99%
2024 741.634.000.000 0.68%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

MediPal Holdings Corporation Assets
Year Assets Growth
2004 848.416.000.000
2005 993.491.000.000 14.6%
2006 1.032.931.000.000 3.82%
2007 1.104.833.000.000 6.51%
2008 1.117.287.000.000 1.11%
2009 1.166.486.000.000 4.22%
2010 1.284.679.000.000 9.2%
2011 1.274.411.000.000 -0.81%
2012 1.328.601.000.000 4.08%
2013 1.400.792.000.000 5.15%
2014 1.454.800.000.000 3.71%
2015 1.497.310.000.000 2.84%
2016 1.525.912.000.000 1.87%
2017 1.621.573.000.000 5.9%
2018 1.617.911.000.000 -0.23%
2019 1.644.279.000.000 1.6%
2020 1.679.934.000.000 2.12%
2021 1.709.474.000.000 1.73%
2022 1.703.871.000.000 -0.33%
2023 1.815.781.000.000 6.16%
2023 1.799.127.000.000 -0.93%
2024 1.814.497.000.000 0.85%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

MediPal Holdings Corporation Liabilities
Year Liabilities Growth
2004 680.312.000.000
2005 751.078.000.000 9.42%
2006 771.820.000.000 2.69%
2007 814.141.000.000 5.2%
2008 822.787.000.000 1.05%
2009 835.494.000.000 1.52%
2010 943.696.000.000 11.47%
2011 920.068.000.000 -2.57%
2012 946.712.000.000 2.81%
2013 993.314.000.000 4.69%
2014 997.198.000.000 0.39%
2015 1.008.984.000.000 1.17%
2016 1.004.749.000.000 -0.42%
2017 1.048.918.000.000 4.21%
2018 1.025.064.000.000 -2.33%
2019 1.036.857.000.000 1.14%
2020 1.041.002.000.000 0.4%
2021 1.060.387.000.000 1.83%
2022 1.015.817.000.000 -4.39%
2023 1.101.166.000.000 7.75%
2023 1.062.513.000.000 -3.64%
2024 1.017.351.000.000 -4.44%

MediPal Holdings Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
17076.42
Net Income per Share
187.36
Price to Earning Ratio
13.86x
Price To Sales Ratio
0.15x
POCF Ratio
14.18
PFCF Ratio
13.99
Price to Book Ratio
0.9
EV to Sales
0.09
EV Over EBITDA
4.37
EV to Operating CashFlow
8.34
EV to FreeCashFlow
8.34
Earnings Yield
0.07
FreeCashFlow Yield
0.07
Market Cap
537,48 Bil.
Enterprise Value
320,28 Bil.
Graham Number
3484.8
Graham NetNet
-619.67

Income Statement Metrics

Net Income per Share
187.36
Income Quality
0.98
ROE
0.07
Return On Assets
0.02
Return On Capital Employed
0.06
Net Income per EBT
0.54
EBT Per Ebit
1.5
Ebit per Revenue
0.01
Effective Tax Rate
0.31

Margins

Sales, General, & Administrative to Revenue
0.04
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.07
Operating Profit Margin
0.01
Pretax Profit Margin
0.02
Net Profit Margin
0.01

Dividends

Dividend Yield
0.02
Dividend Yield %
2.31
Payout Ratio
0
Dividend Per Share
60

Operating Metrics

Operating Cashflow per Share
183.2
Free CashFlow per Share
183.2
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0.06
Return on Tangible Assets
0.02
Days Sales Outstanding
79.07
Days Payables Outstanding
103.83
Days of Inventory on Hand
19.26
Receivables Turnover
4.62
Payables Turnover
3.52
Inventory Turnover
18.95
Capex per Share
0

Balance Sheet

Cash per Share
1.037,17
Book Value per Share
3.800,95
Tangible Book Value per Share
3602.87
Shareholders Equity per Share
2880.67
Interest Debt per Share
0.03
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
-2.96
Current Ratio
1.23
Tangible Asset Value
755,60 Bil.
Net Current Asset Value
233,44 Bil.
Invested Capital
543861000000
Working Capital
233,44 Bil.
Intangibles to Total Assets
0.02
Average Receivables
800,16 Bil.
Average Payables
936,47 Bil.
Average Inventory
174003000000
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

MediPal Holdings Corporation Dividends
Year Dividends Growth
2001 12
2002 12 0%
2003 12 0%
2004 12 0%
2005 12 0%
2006 11 -20%
2007 15 33.33%
2008 22 28.57%
2009 16 -31.25%
2010 18 11.11%
2011 18 0%
2012 18 0%
2013 22 18.18%
2014 24 8.33%
2015 25 4%
2016 30 16.67%
2017 32 6.25%
2018 36 11.11%
2019 40 10%
2020 42 4.76%
2021 42 0%
2022 44 4.55%
2023 53 16.98%
2024 60 11.67%
2025 0 0%

MediPal Holdings Corporation Profile

About MediPal Holdings Corporation

Medipal Holdings Corporation engages in the prescription pharmaceutical wholesale business in Japan. It procures healthcare products related to diagnostics, testing, treatment, and administration comprises medical equipment and medical materials, and clinical diagnostic reagents for use from the pre-symptomatic stage; handles PMS services on contract for manufacturers; and invests in orphan drugs and other products. The company is also involved in the wholesale of cosmetics, daily necessities, and OTC pharmaceuticals; animal health products for companion animals; food processing raw materials for agriculture, fisheries, and livestock; and livestock feed additives, seasonings, veterinary medical equipment, packaging materials, industrial chemicals, and other products. In addition, it engages in the contract-based epidemiological studies, clinical studies, etc.; creation of a computerized medical supply database and master product databases for medical facilities; health insurance claims reviews, medical coding dispatch, outsourcing, and remote education activities; life and non-life insurance agency business; cleaning management; management and operation of distribution centers; commissioned delivery and worker dispatch business; and planning, management, administration, and product and service development for the class A health dispensing pharmacies service brand. Medipal Holdings Corporation serves hospitals, clinics, dispensing pharmacies, drugstores, home centers, convenience stores, supermarkets, discount stores, animal hospitals, livestock and fishery businesses, and processed food manufacturers. The company was formerly known as Mediceo Paltac Holdings Co., Ltd. and changed its name to Medipal Holdings Corporation in October 2009. Medipal Holdings Corporation was founded in 1898 and is headquartered in Tokyo, Japan.

CEO
Mr. Shuichi Watanabe
Employee
13.075
Address
2-7-15, Yaesu
Tokyo, 104-8461

MediPal Holdings Corporation Executives & BODs

MediPal Holdings Corporation Executives & BODs
# Name Age
1 Mr. Yasuhiro Choufuku
Executive Vice President & Director
70
2 Mr. Shinjiro Watanabe
GM of Information Systems Management Division & Director
70
3 Mr. Shuichi Watanabe
Chief Compliance Officer, Chief Executive Officer, President & Representative Director
70
4 Mr. Yuji Sakon
MD, GM of Administration Division & Director
70
5 Mr. Toshihide Yoda
Senior MD of Investor Relations, GM of Business Development Department & Director
70

MediPal Holdings Corporation Competitors